Screener
Travere Therapeutics, Inc. TVTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Assets | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Accounts payable | $12,912 | $24,800 |
| Accrued expenses | 104,408 | 126,035 |
| Operating lease liabilities, current portion | 6,017 | 5,875 |
| Other current liabilities | 2,100 | 3,194 |
| Total current liabilities | 125,437 | 159,904 |
| Convertible debt | 312,079 | 311,724 |
| Operating lease liabilities, less current portion | 9,566 | 11,134 |
| Other non-current liabilities | 9,378 | 7,601 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s accrued expenses?
- Travere Therapeutics, Inc. (TVTX) reported accrued expenses of $2.1M in Q1 2026.
- How has Travere Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Travere Therapeutics, Inc.'s accrued expenses decreased by 86.7% year-over-year, from $15.76M to $2.1M.
- What is the long-term trend for Travere Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s accrued expenses has grown at a -11.8% compound annual growth rate (CAGR), from $5.98M to $3.19M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Travere Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude